Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-0482PMID 19737946PMCID PMC3417101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

  2008cited by this paper
• Sunitinib Induces Hypothyroidism in Advanced Cancer Patients and May Inhibit Thyroid Peroxidase Activity

  2007cited by this paper
• A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.

  2007cited by this paper
• Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

  2007cited by this paper
• Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

  2006influential reference
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

  2006cited by this paper
• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  2006cited by this paper
• Angiogenesis inhibitors and hypertension: an emerging issue.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)

  2005cited by this paper
• Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

  2005cited by this paper
• Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

  2005cited by this paper
• A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

  2004cited by this paper
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  2004cited by this paper
• Biology of gastrointestinal stromal tumors.

  2004cited by this paper
• Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).

  2004cited by this paper
• SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

  2004cited by this paper
• Protein Kinase C θ (PKCθ) Expression and Constitutive Activation in Gastrointestinal Stromal Tumors (GISTs)

  2004cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

  2003cited by this paper
• 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

  2003cited by this paper
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

  2003cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002influential reference
• Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.

  2002cited by this paper
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

  1999cited by this paper

• The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib

  2026cites this paper
• Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modeling

  2025cites this paper
• Regulatory roles of non-coding RNAs in programmed cell death pathways and drug resistance in gastrointestinal stromal tumors

  2025cites this paper
• English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology

  2024cites this paper
• Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance

  2024cites this paper
• TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors

  2023cites this paper
• 2023 GEIS Guidelines for gastrointestinal stromal tumors

  2023cites this paper
• Pharmacokinetics and pharmacodynamic evaluation of hyaluronic acid-modified imatinib-loaded PEGylated liposomes in CD44-positive Gist882 tumor-bearing mice

  2023cites this paper
• Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.

  2023cites this paper
• Radiological Evaluation of a Malignant Gastrointestinal Stromal Tumor in a Female Patient With the Coincidental Detection of Primary Breast Cancer: A Case Report

  2023cites this paper
• Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib

  2022cites this paper
• Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature

  2022cites this paper
• Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST) - a Systematic Review.

  2022cites this paper
• Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?

  2022cites this paper
• Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis

  2022cites this paper
• Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor

  2022cites this paper
• An updated review of the treatment landscape for advanced gastrointestinal stromal tumors

  2021cites this paper
• Whole-exome Sequencing Analysis for Mutations Characteristics in Recurrent or Metastatic Gastrointestinal Stromal Tumors

  2021cites this paper
• A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients

  2021cites this paper
• Gastrointestinal stromal tumours

  2021cites this paper
• Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway

  2021cites this paper
• Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.

  2021cites this paper
• Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor

  2021cites this paper
• Therapeutic Drug Monitoring Of Sunitinib in Gastrointestinal Stromal Tumors and Metastatic Renal Carcinoma in Adults - A Review.

  2020cites this paper
• HIF-1α regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors

  2020cites this paper
• Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress

  2020cites this paper
• Second line of therapy for gastrointestinal stromal tumors: is there a choice?

  2019cites this paper
• Second- and Third-Line Treatment

  2019cites this paper
• KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development

  2019cites this paper
• Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours

  2019cites this paper
• The Proceedings of the 19th International Cancer Imaging Society Meeting and Annual Teaching Course

  2019cites this paper
• Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

  2019cites this paper
• Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence

  2019cites this paper
• Predictive factors of response to Sunitinib in Imatinib-Resistant Gastrointestinal Stromal 1 Tumors ( GISTs ) : A multi-institutional study 2

  2019cites this paper
• Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

  2019cites this paper
• CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance

  2018cites this paper
• Gastrointestinal Stromal Tumors.

  2018cites this paper
• Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 243 Pharmacometrics to improve clinical benefit assessment in oncology

  2017cites this paper
• Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review

  2017cites this paper
• Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.

  2017cites this paper
• An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure

  2017cites this paper
• Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor

  2017cites this paper
• Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

  2017cites this paper
• Cancer as a Paradigm for Translational and Clinical Biomedical Research

  2017cites this paper
• Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021

  2016cites this paper
• Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

  2016cites this paper
• Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial

  2016cites this paper
• PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor

  2016cites this paper
• Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

  2016cites this paper
• Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches

  2016cites this paper
• Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives

  2016cites this paper
• Receptor tyrosine kinase inhibitors: Are they real tumor killers?

  2016cites this paper
• Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors

  2016cites this paper
• Gastric gastrointestinal stromal tumor: Does the newly proposed UICC TNM staging system provide better prognostic ability than the National Institutes of Health consensus criteria?

  2016cites this paper
• Tales of Personalized Cancer Treatment.

  2016cites this paper
• Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

  2016cites this paper
• Progress of Multimodal Molecular Imaging Technology in Diagnosis of Tumor

  2016cites this paper
• The value of 18F‐fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta‐analysis

  2016cites this paper
• Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors.

  2016cites this paper
• Factores pronósticos de recurrencia y supervivencia en tumores del estroma gastrointestinal. Experiencia del Hospital de Oncología Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social

  2015cites this paper
• Молекулярно-генетические особенности и маркеры гастроинтестинальных стромальных опухолей

  2015cites this paper
• Targeted Therapy in Gastrointestinal Stromal Tumors

  2015cites this paper
• Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.

  2015cites this paper
• Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor

  2015cites this paper
• Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

  2015cites this paper
• Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib

  2015cites this paper
• Therapeutic targets in gastrointestinal stromal tumors

  2015cites this paper
• Gastrointestinal Stromal Tumor (GIST)

  2015cites this paper
• Dose optimization of oral targeted therapies in oncology

  2015cites this paper
• Gastrointestinal Stromal Tumors (GIST)—Paving the Way for Modern Oncology—Epidemiology, Diagnosis, Treatment

  2015cites this paper
• Imaging-Based Treatment Adaptation in Radiation Oncology

  2015cites this paper
• Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors.

  2015cites this paper
• Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor

  2015cites this paper
• Contrast‐enhanced endoscopic ultrasonography can predict a higher malignant potential of gastrointestinal stromal tumors by visualizing large newly formed vessels

  2015cites this paper
• Targeted Therapy for Gastrointestinal Stromal Tumor : Emerging concepts in oncogenetics and therapy sequencing

  2015cites this paper
• Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib

  2015cites this paper
• PET/CT imaging in cancer: Current applications and future directions

  2014cites this paper
• Effect of gastrointestinal resection on sunitinib exposure in patients with GIST

  2014cites this paper
• Functional and molecular imaging in cancer drug development.

  2014cites this paper
• Imatinib: A Breakthrough of Targeted Therapy in Cancer

  2014cites this paper
• Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer

  2014cites this paper
• The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide

  2014cites this paper
• The role of inflammation in sarcoma.

  2014cites this paper
• Gastrointestinal Stromal Tumors in the 21 st Century

  2014cites this paper
• Making sense of dietary calcium and urinary stone disease

  2014cites this paper
• Functional and molecular imaging in cancer drug development

  2014cites this paper
• Positron Emission Tomography in Bone and Soft Tissue Tumors

  2014cites this paper
• Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

  2014cites this paper
• Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor.

  2013cites this paper
• Giant extra gastrointestinal stromal tumor of lesser omentum obscuring the diagnosis of a choloperitoneum.

  2013cites this paper
• Gastrointestinal Stromal Tumors: From Molecular Pathogenesis to Therapy

  2013cites this paper
• Facteurs prédictifs d’efficacité des anticorps anti-angiogéniques de la voie du VEGF

  2013cites this paper
• Studies in GIST with emphasis on treatment response evaluation with FDG PET.

  2013cites this paper
• Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

  2013cites this paper
• Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

  2012cites this paper
• Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

  2012cites this paper
• The complexity of sunitinib dosing in renal cell cancer patients

  2012cites this paper
• Current management and prognostic features for gastrointestinal stromal tumor (GIST)

  2012cites this paper
• Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group

  2012cites this paper